




**Statement of stand-alone Financial Results for the quarter ended 30<sup>th</sup> June, 2012**

Rs. lakhs

<b>PART I : STATEMENT OF STAND-ALONE RESULTS</b>				
<b>PARTICULARS</b>	<b>THREE MONTHS ENDED</b>			<b>YEAR ENDED (AUDITED)</b>
	<b>30-JUN-2012 REVIEWED</b>	<b>31-MAR-2012 UN-AUDITED</b>	<b>30-JUN-2011 REVIEWED</b>	<b>31-MAR-2012</b>
01. Gross Sales / Income from Operations	11663	12133	9728	44150
Less : Excise Duty	478	308	323	1347
Less : Sales Tax	327	304	202	1119
Net Sales / Income from Operations	10858	11521	9203	41684
02. Other Operating Income	637	931	458	2508
<b>03. TOTAL INCOME FROM OPERATIONS</b>	<b>11495</b>	<b>12452</b>	<b>9661</b>	<b>44192</b>
<b>04. EXPENDITURE</b>				
a) Cost of materials consumed	4438	3413	3008	11768
b) Purchases of stock-in-trade	195	330	341	1553
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-1389	-42	-68	75
d) Employee benefits expense	1866	1814	1456	6487
e) Depreciation and amortization expense	432	378	378	1541
f) Other Expenses	3368	3965	2399	12548
<b>TOTAL EXPENSES</b>	<b>8910</b>	<b>9858</b>	<b>7514</b>	<b>33972</b>
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	2585	2594	2147	10220
06. Other Income	168	74	105	327
07. Finance costs	444	609	530	2296
08. Profit / (Loss) from ordinary activities before tax	2309	2059	1722	8251
09. Tax expense, including deferred tax	491	606	345	2038
10. Net Profit / Loss (-) from ordinary activities after tax	1818	1453	1377	6213
11. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3115	3115	2815	3115
12. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year				43632
13. Earnings per share – Basic and diluted EPS before and after extraordinary item (Rs.) – non-annualized	5.84	5.00	4.89	21.39
	5.84	5.00	4.89	21.39
<b>PART II : SELECT INFORMATION</b>				
14. Public Shareholding:				
a) Number of Shares	13,378,081	13,378,081	10,448,455	13,378,081
b) Percentage of Shareholding	42.95	42.95	37.12	42.95
15. Promoters and Promoter Group Shareholding				
a) Pledged / Encumbered – No. of shares	-	-	1,050,000	-
Percentage (as a % of the total shareholding of promoter and promoter group)	-	-	5.93	-
Percentage (as a % of the total share capital of the company)	-	-	3.73	-
b) Non – encumbered – No. of shares	-	-	-	-
Percentage (as a % of the total shareholding of promoter and promoter group)	17,769,881	17,769,881	16,649,497	17,769,881
Percentage (as a % of the total share capital of the company)	100.00	100.00	94.07	100.00
	57.05	57.05	59.15	57.05

Dated at Hyderabad, this, the 11<sup>th</sup> day of August, 2012.  
for and on behalf of the Board of Directors,  
**NATCO Pharma Limited**

  
V.C. Nannapaneni  
Chairman & Managing Director

**Status of Investor Complaints as at 30th June, 2012**

Pending as on 01-04-2012	Nil
Received during the quarter	63
Resolved during the quarter	63
Pending as on 30-06-2012	Nil



**Statement of consolidated Financial Results for the quarter ended 30<sup>th</sup> June, 2012**

Rs. lakhs

<b>PART I : STATEMENT OF CONSOLIDATED RESULTS</b>				
<b>PARTICULARS (REFER NOTES BELOW)</b>	<b>THREE MONTHS ENDED (UNREVIEWED/UNAUDITED)</b>			<b>YEAR ENDED (AUDITED)</b>
	<b>30-JUN-2012</b>	<b>31-MAR-2012</b>	<b>30-JUN-2011</b>	<b>31-MAR-2012</b>
01. Gross Sales / Income from Operations	14252	14459	11843	52953
Less : Excise Duty	478	308	323	1347
Less : Sales Tax	327	304	202	1119
Net Sales / Income from Operations	13447	13847	11318	50487
02. Other Operating Income	637	925	457	2605
03. TOTAL INCOME FROM OPERATIONS	14084	14772	11775	53092
04. EXPENDITURE				
a) Cost of materials consumed	6511	5372	4410	18660
b) Purchases of stock-in-trade	195	330	341	1553
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-1389	-42	-68	75
d) Employee benefits expense	2143	2176	1847	7777
e) Depreciation and amortization expense	443	166	402	1583
f) Other Expenses	3726	4353	2636	13478
TOTAL EXPENSES	11629	12355	9568	43126
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	2455	2417	2207	9966
06. Other Income	178	74	117	350
07. Finance costs	467	621	548	2362
08. Profit / (Loss) from ordinary activities before tax	2166	1870	1776	7954
09. Tax expense, including deferred tax	491	619	402	2107
10. Minority Interest	-32	-14	-29	-114
11. Net Profit / Loss (-) from ordinary activities after tax	1707	1265	1403	5961
12. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3115	3115	2815	3115
13. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year				44086
14. Earnings per share – Basic and diluted EPS before and after extraordinary item (Rs.)	5.48	4.35	4.98	20.53
	5.48	4.35	4.98	20.53
<b>PART II : SELECT INFORMATION</b>				
15. Public Shareholding:				
a) Number of Shares	13,378,081	13,378,081	10,448,455	13,378,081
b) Percentage of Shareholding	42.95	42.95	37.12	42.95
16. Promoters and Promoter Group Shareholding				
a) Pledged / Encumbered – No. of shares			1,050,000	
Percentage (as a % of the total shareholding of promoter and promoter group)			5.93	
Percentage (as a % of the total share capital of the company)			3.73	
b) Non – encumbered – No. of shares				
Percentage (as a % of the total shareholding of promoter and promoter group)	17,769,881	17,769,881	16,649,497	17,769,881
Percentage (as a % of the total share capital of the company)	100.00	100.00	94.07	100.00
	57.05	57.05	59.15	57.05

The above financial results were approved by the Audit Committee and the Board of Directors at a meeting held at Hyderabad, on Saturday, the 11<sup>th</sup> August, 2012. There are no exceptional and extraordinary items to be reported for the period under review. The stand-alone results are available on the company's web-site [www.natcopharma.co.in](http://www.natcopharma.co.in). In respect of reference relating to non-accounting of minimum alternate tax credit, the company will review the position during the current financial year.

Dated at Hyderabad, this, the 11<sup>th</sup> August, 2012.  
for and on behalf of the Board of Directors,  
NATCO Pharma Limited

V.C. Nannapaneni  
Chairman & Managing Director

**Status of Investor Complaints as at 30<sup>th</sup> June, 2012**

Pending as on 01-04-2012	Nil
Resolved during the quarter	63
Resolved during the quarter	63
Pending as on 30-06-2012	Nil



**Report of segment wise revenue, Results and Capital Employed, (Un-audited) under Clause 41 of the Listing Agreement, for the quarter ended on 30<sup>th</sup> June, 2012**

*Rs. lakhs*

	THREE MONTHS ENDED			PREVIOUS ACCOUNTING YEAR ENDED (UN-AUDITED)
	30-JUN-2012	31-MAR-2012	30-JUN-2011	31-MAR-2012
<b>01. Segment Revenue (Net)</b>				
a) Bulk Chemicals	3970	3518	4285	15662
b) Formulations	7056	8113	5328	27126
c) Job Work	156	205	230	896
<b>Total</b>	<b>11182</b>	<b>11836</b>	<b>9843</b>	<b>43684</b>
Less : Inter-segment Revenue	479	221	289	1521
Add : Other unallocable income	960	911	212	2356
<b>Net Sales / Income from Operations</b>	<b>11663</b>	<b>12526</b>	<b>9766</b>	<b>44519</b>
<b>02. Segment Results : Profit (+)/Loss (-) before tax and interest</b>				
a) Bulk Chemicals	653	520	783	2943
b) Formulations	2925	1805	2212	9688
c) Job Work	116	169	189	727
<b>Total</b>	<b>3694</b>	<b>2494</b>	<b>3184</b>	<b>13358</b>
Less : a) Interest	444	609	530	2296
b) Other allocable expenditure net of unallocable income	941	-174	932	2811
<b>Total Profit Before Tax</b>	<b>2309</b>	<b>2059</b>	<b>1722</b>	<b>8251</b>
<b>03. Capital Employed (Segment Assets - Segment Liabilities)</b>				
a) Bulk Chemicals	33382	32093	23141	32093
b) Formulations	29671	28721	22320	28721
c) Job Work	118	178	277	178
d) Unallocated (Others)	-14606	-14246	-9902	-14246
<b>Total</b>	<b>48565</b>	<b>46746</b>	<b>35836</b>	<b>46746</b>

The above un-audited financial results were reviewed by the Audit Committee, Statutory Auditors and approved by the Board of Directors at a meeting held at Hyderabad, on Saturday, the 11<sup>th</sup> August, 2012. There are no exceptional and extraordinary items to be reported for the period under review. In respect of non-accounting of minimum alternate tax credit, referred to in the review report, the company will evaluate the position during the current financial year. Figures for the previous period(s) have been re-arranged / re-grouped wherever necessary. The figures for the quarter ended March 31, 2012 are the balancing figures between the audited figures in respect of the full financial year and published year to date figures up to third quarter of the relevant financial year, except those relating to segment revenues and profitability.

Dated at Hyderabad, this, the 11<sup>th</sup> day of August, 2012.  
for and on behalf of the Board of Directors,  
NATCO Pharma Limited

  
V.C. Nannapaneni  
Chairman & Managing Director

Regd. Office: **NATCO** House, Road # 2, Banjara Hills, **Hyderabad : 500 033.**